Equity Research Report: Alembic Pharmaceuticals Ltd.
Date: February 7, 2026 (Note: Analysis based on latest verified financial data available up to FY25/Q3 FY25).
Market Price (CMP): ₹798 (approx)
Market Cap: ₹15,706 Cr
Sector: Pharmaceuticals
1️⃣ Business Model & Work
Company Overview:
Alembic Pharmaceuticals ek fully integrated pharmaceutical company hai jo 1907 se establish hai. Ye company purani aur trusted brand “Alembic” (Glycodin fame) ka hissa hai. Inka main kaam generic drugs (dawaiyan) banana aur bechna hai.
Revenue Sources (Approximate Split):
- International Generics (US & Ex-US): ~45-50% (US sabse bada market hai, par Ex-US growth fast hai).
- Domestic Formulations (India): ~35% (Branded Generics – Cold, Cough, Gastric segments me strong hold hai).
- API (Active Pharmaceutical Ingredients): ~15-20% (Raw material dusri companies ko bechte hain).
Competitive Advantage:
- R&D Focus: Revenue ka ek bada hissa (~12-14% historically) R&D par kharch karte hain, jo complex generics banane me help karta hai.
- Manufacturing Scale: Inke paas state-of-the-art facilities hain (FDA approved), lekin pichle kuch saalon me heavy Capex (kharcha) kiya hai naye plants (F2, F3, F4) par.
2️⃣ Industry & Sector Analysis
Status: Defensive & Secular Growth
Pharma sector India me secular hai (long-term demand always exists). Current phase me US Generic market me “Price Erosion” (daam girna) stabilize ho raha hai, jo Indian exporters ke liye positive hai.
Growth Drivers:
- US Patent Cliffs: Bahut saari badi drugs ke patent expire ho rahe hain, jiska generic version banane ka moka Alembic jaise players ko milega.
- Domestic Demand: India me chronic diseases (Sugar, BP) badhne se Branded formulations ka business steady grow kar raha hai.
- China + 1: Global players API sourcing ke liye China ke alawa India ko prefer kar rahe hain.
Major Competitors:
Sun Pharma, Lupin, Cipla, Torrent Pharma, Zydus Lifesciences.
3️⃣ Latest Financial Performance (Verified Data)
Data Source: Screener.in & Yahoo Finance (Consolidated)
Note: Numbers are in ₹ Crores except EPS.
| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM (Latest 12M) |
| Revenue | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 |
| Operating Profit (EBITDA) | 1,480 | 874 | 682 | 932 | 1,008 |
| OP Margin (%) | 27% | 16% | 12% | 15% | 15% |
| Net Profit (PAT) | 1,146 | 521 | 342 | 616 | 582 |
| EPS (₹) | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 |
Recent Quarterly Trends (Q3 FY25 – Dec 2024):
- Sales: ~₹1,693 Cr (Steady growth confirmed).
- Net Profit: ~₹138 Cr.
- Margins: Operating margins ~15-16% range me stabilize hue hain after a dip in FY23.
Key Ratios:
- ROE: ~11.9% (Last 3 years average is low due to heavy capex).
- ROCE: ~13.0% (Improving slightly).
- Debt/Equity: 0.28 (Comfortable levels, debt reduce ho raha hai).
- Interest Coverage: ~10x (Healthy).
4️⃣ Management & Shareholding (Latest)
Shareholding Pattern (Dec 2024 / Latest Available):
| Category | Holding (%) | Trend |
| Promoters | 69.74% | ✅ High & Stable (Shows confidence) |
| FIIs | 4.24% | 🔻 Slight Decrease |
| DIIs (Mutual Funds) | ~16-17% | 🔼 Stable/Increasing |
| Public | ~10% | – |
- Promoter Pledging: None / Negligible. (Clean ownership).
- Management Quality: Chirayu Amin group manage karta hai. Execution history strong hai, lekin pichle 3 saal me heavy Capex (expansion) ki wajah se profits par pressure tha. Governance issues major nahi hain.
5️⃣ Valuation (Latest Market Data)
Current Valuation:
- PE Ratio: ~25.1x
- Price to Book (PB): 2.95x
- Industry PE: ~32x
Peer Comparison:
- Sun Pharma: ~33x PE (Premium valuation)
- Cipla: ~22-23x PE
- Alembic Pharma: ~25x PE
Interpretation:
Valuation “Reasonable / Undervalued relative to Historical Average”.
Historically, Alembic 25-30x PE command karta tha jab US business peak par tha. Abhi ye apne historical average ke lower band par trade kar raha hai kyunki pichle 2 saal se earnings depressed thin.
6️⃣ Future Growth Triggers (3–5 Years)
- New Facilities Commercialization:Company ne F2, F3, aur F4 plants par bhari kharcha kiya tha. Ye plants ab US FDA se clear ho rahe hain. Jaise-jaise yahan se production badhega, “Operating Leverage” play out karega (Sales badhegi par kharcha utna nahi badhega -> More Profit).
- US Product Launches:Recent approvals (jaise Travoprost Ophthalmic aur Difluprednate) indicate kar rahe hain ki company complex products (Injectables, Ophthalmic) me enter kar rahi hai jahan competition kam aur margin zyada hota hai.
- Animal Health Business:Halaanki ye chhota segment hai, par consistent double-digit growth dikha raha hai.
7️⃣ Present Situation (Current Outlook)
- Current Phase: “Recovery & Consolidation Phase”.Stock ek lambe correction (price girne) ke baad base bana raha hai. Heavy capex cycle khatam ho chuka hai, ab cash flow generate karne ka time hai.
- News Impact: Recent US FDA approvals positive hain. Q3 results mixed to stable hain (Sales growth hai par margins par abhi bhi pressure hai due to freight/cost).
- Outlook:
- Short Term: Range-bound (₹750 – ₹850 range).
- Long Term: Bullish, jaise hi new plants ki utilization 50-60% cross karegi.
8️⃣ Risk & Red Flags
- US FDA Inspections (Biggest Risk):Pharma companies ke liye US FDA ka “Observation” ya “Warning Letter” sabse bada risk hota hai. Alembic ke Halol ya Jarod plants par koi negative news stock ko 10-20% gira sakti hai.
- Pricing Pressure:US generic market me daam girne ka trend abhi poori tarah khatam nahi hua hai.
- Low ROE:Naye plants abhi poora profit nahi de rahe, isliye ROE (~11%) historically low hai. Ise wapas 18-20% jaane me time lagega.
9️⃣ Final Verdict
- Summary: Alembic Pharma ek high-quality company hai jo currently apne “Investment Phase” se nikal kar “Harvesting Phase” me aa rahi hai. Balance sheet strong hai (Low Debt).
- Long-term Investors: SUITABLE. Agar aap 3-5 saal hold kar sakte hain, to current valuation attractive hai. Capex ka fal aane wale saalon me milega.
- Conservative Investors: Avoid karein. Sector leaders (Sun Pharma/Cipla) zyada stable hain. Alembic mid-cap hone ki wajah se volatile hai.
- Aggressive Investors: Good bet for turnaround.
- Target Range (Estimated): Historical valuation (25x PE) aur FY26/27 earnings estimates ke hisab se, downside limited lagta hai.
Actionable Step:
Agar aap risk le sakte hain, to current levels (₹780-800) par Sip/Staggered Buying shuru kar sakte hain. Agar portfolio me already hai, to HOLD karein, loss me bechne ka reason nahi dikh raha.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.